| Literature DB >> 12034801 |
Y Suzuki1, K Imai, Y Toribe, H Ueda, K Yanagihara, K Shimono, T Okinaga, J Ono, T Nagai, T Matsuoka, T Tagawa, J Abe, Y Morita, Y Fujikawa, H Arai, T Mano, S Okada.
Abstract
The long-term effectiveness of zonisamide (ZNS) was evaluated in 11 patients with West syndrome (7 symptomatic) who had cessation of spasms with ZNS monotherapy. During the follow-up period (24 to 79 months, mean = 53 months), this response was maintained in 7 patients (3 symptomatic, relapse rate = 36%), including 2 children in whom ZNS was successfully discontinued. No serious adverse reactions were noted. ZNS may be both effective and well tolerated for the treatment of West syndrome.Entities:
Mesh：
Substances：
Year: 2002 PMID： 12034801 DOI： 10.1212/wnl.58.10.1556
Source DB: PubMed Journal: Neurology ISSN： 0028-3878 Impact factor: 9.910